This purified ABfinity™ recombinant rabbit monoclonal antibody recognizes Creb [pS133].

ABfinity™ Creb [pS133] antibody advantages include:

•  Superior lot-to-lot consistency
•  Extremely high specificity and sensitivity
• Recombinant rabbit monoclonal antibody
• Validation in Western blot

Specific for Creb [pS133]
CREB (cAMP responsive element binding protein) is a 37kDa transcription factor that belongs to the leucine zipper family (Ref 1). It binds to the cyclic-AMP response element as a homodimer (Ref 2). Upon hormone-dependent stimulation of the cyclic-AMP pathway, phosphorylated CREB1 acts as an inducer of transcription. CREB is phosphorylated at Ser133 by various signaling pathways including Ca2+ and stress signaling (Ref 3, 4). CREB1 is known to play important role in memory formation (Ref 2, 5). Aberration in CREB-mediated gene expression has been linked with Alzheimer disease hippocampus (Ref 6).

Exceptional Consistency Helps Save You Time and Money
ABfinity™ antibodies are produced by transfection of mammalian cells with heavy and light chain antibody cDNAs. This provides you with high consistency between lots, minimizing the need to revalidate your assays for each lot.

High Specificity Means More Reliable Data
The proprietary recombinant technology employed in the production of ABfinity™ antibodies permits an extremely high degree of reliability. Staining of nonspecific proteins is virtually eliminated while very high sensitivity is achieved. Invitrogen has validated this antibody in Western blotting (Fig 1).

High Sensitivity Lets You Detect Low Levels of Target Protein
ABfinity™ antibodies demonstrate much higher sensitivity than ordinary antibodies. Proteins expressed in low levels can be detected with high specificity allowing you to use less of your precious samples than with ordinary antibodies.

Recombinant Rabbit IgG—Use Like Any Other IgG Antibody
As with traditional IgG antibodies, gel electrophoresis of ABfinity™ antibodies produces a 150kDa band under non-reducing conditions, and 50kDa and 25kDa bands under reducing conditions.

For Research Use Only. Not intended for any animal or human therapeutic or diagnostic use.

Related Links
•  Learn more about the superior performance of ABfinity™ recombinant monoclonal antibodies.
•  See Invitrogen's full line of ABfinity™ recombinant monoclonal antibodies.

References

  1. Hoeffler, J.P., Meyer, T.E., Yun, Y., Jameson, J.L., and Habener, J.F. (1988). Cyclic AMP-responsive DNA-binding protein: structure based on a cloned placental cDNA. Science  242, 1430-1433.
  2. Bartsch, D., Casadio, A., Karl, K.A., Serodio, P., and Kandel, E.R. (1998). CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation. Cell 95, 211-223.
  3. Tan, Y., Rouse, J., Zhang, A., Cariati, S., Cohen, P., and Comb, M.J. (1996). FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. The EMBO journal 15, 4629-4642.
  4. Xing, J., Kornhauser, J.M., Xia, Z., Thiele, E.A., and Greenberg, M.E. (1998). Nerve growth factor activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways to stimulate CREB serine 133 phosphorylation. Molecular and Cellular Biology 18, 1946-1955.
  5. Dash, P.K., Hochner, B., and Kandel, E.R. (1990). Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature 345, 718-721.
  6. Satoh, J, Tabunoki, H., and Arima, K. (2009). Molecular network analysis suggests aberrant CREB-mediated gene regulation in the Alzheimer disease hippocampus. Disease Markers 27, 239-252.